Theravance Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview

Theravance Biopharma

06/05/2025 21:44

Theravance Biopharma Inc TBPH.OQ TBPH.O is expected to show a rise in quarterly revenue when it reports  results on May 8 for the period ending March 31 2025

The George Town Grand Cayman-based  company is expected to report a 6.9% increase in revenue to $15.5 million from $14.5 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Theravance Biopharma Inc is for a loss of 23 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Theravance Biopharma Inc is $13.50​, above​ its last closing price of $10.29. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.25
-0.21
-0.31
Missed
-47.6
Sep. 30 2024
-0.24
-0.23
-0.26
Missed
-12.6
Jun. 30 2024
-0.22
-0.21
-0.28
Missed
-35.6​
Mar. 31 2024
-0.22
-0.25
-0.24
Beat
5.5
​​Dec. 31 2023
-0.17
-0.15
-0.17
Missed
-14.3
Sep. 30 2023
-0.22
-0.21
-0.17
Beat
18.9​
Jun. 30 2023
-0.22
-0.21
-0.28
Missed
-33.3
Mar. 31 2023
-0.25
-0.25
-0.35
Missed
-42.1

This summary was machine generated May 6 at 20:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)